Demographic and thalamic activation data during vagus nerve stimulation
| Thalamic activation during VNS | |||||
|---|---|---|---|---|---|
| Patient No/age (years)/sex/seizure focus/anticonvulsant | NCP implanted before scanning | Frequency* | Clinical improvement (%) | Cluster extent (voxel) | p Value |
| *Number of seizures/month on average before the implantation. | |||||
| BTL, bilateral temporal lobes; F, female; LTL: left temporal lobe; M, male; RFTL, right frontal temporal lobe; RTL, right temporal lobe; VNS, vagus nerve stimulation. | |||||
| 1/27/M/BTL/topiramate, valproic acid | 1 month | 10 | 0% | 0 | |
| 2/29/F/RFTL/carbamazepine | 2 months | 0.7 | +75% | 22 | p< 2.7x10−4 |
| 3/26/M/RTL/carbamazepine | 11 months | 4 | 0% | 0 | |
| 4/40/M/RTL/topiramate, valproic acid | 6 months | 4 | 0% | 0 | |
| 5/40/M/LTL/topiramate, valproic acid | 5 months | 1 | +50% | 5 | p< 3.6×10−6 |